US 11,719,705 B2
IL-17F and IL-17A-specific capture agents, compositions, and methods of using and making
Heather Agnew, Culver City, CA (US); Bert Tsunyin Lai, Culver City, CA (US); Suresh Mark Pitram, La Jolla, CA (US); Blake Farrow, Pasadena, CA (US); James R. Heath, South Pasadena, CA (US); David Bunck, Pasadena, CA (US); Jingxin Liang, Pasadena, CA (US); Arundhati Nag, Pasadena, CA (US); and Samir Das, Pasadena, CA (US)
Assigned to INDI MOLECULAR, INC., Culver City, CA (US); and CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, CA (US)
Filed by Indi Molecular, Inc., Culver City, CA (US); and California Institute of Technology, Pasadena, CA (US)
Filed on Jun. 15, 2018, as Appl. No. 16/10,347.
Claims priority of provisional application 62/617,944, filed on Jan. 16, 2018.
Claims priority of provisional application 62/520,307, filed on Jun. 15, 2017.
Prior Publication US 2018/0364253 A1, Dec. 20, 2018
This patent is subject to a terminal disclaimer.
Int. Cl. G01N 33/68 (2006.01); C07K 7/06 (2006.01); C07K 14/54 (2006.01)
CPC G01N 33/6869 (2013.01) [C07K 7/06 (2013.01); C07K 14/54 (2013.01)] 40 Claims
 
1. A capture agent for a target, the capture agent comprising two or more ligands covalently linked to each other, wherein the ligands each specifically bind to one of two or more distinct epitopes of the target that are in different locations on the target,
wherein the capture agent comprises a first of the ligands having specific affinity for a first of the epitopes, a second of the ligands having specific affinity for a second of the epitopes, and a linker covalently connecting the first ligand to the second ligand,
wherein the target is IL-17A, IL-17F, or both IL-17A and IL-17F,
wherein the first epitope comprises the amino acid sequence FFQKPES (SEQ ID NO:1) or the amino acid sequence PNSEDKNFPRTVMVNL (SEQ ID NO:43), wherein the second epitope comprises the amino acid sequence NENQRVS (SEQ ID NO:3) or the amino acid sequence PNSEDKNFPRTVMVNL (SEQ ID NO:43),
wherein the first ligand comprises a first peptide having an amino acid sequence 80-100% identical to an amino acid sequence selected from the group consisting of rhfrl (SEQ ID NO:44), nrfff (SEQ ID NO:45), rkhyh (SEQ ID NO:46), rrATS (SEQ ID NO:47), rrAQS (SEQ ID NO:48), rrats (SEQ ID NO:49), and rraqs (SEQ ID NO:50),
wherein the second ligand comprises a second peptide having an amino acid sequence 80-100% identical to an amino acid sequence selected from the group consisting of KYGEV (SEQ ID NO:11), LYGEV (SEQ ID NO:12), VHKSG (SEQ ID NO:13), VHLSG (SEQ ID NO:14), QKHGP (SEQ ID NO:15), TKHGP (SEQ ID NO:16), QLHGP (SEQ ID NO:17), TLHGP (SEQ ID NO:18), YDLQR (SEQ ID NO:19), YDLTR (SEQ ID NO:20), YDKQR (SEQ ID NO:21), YDKTR (SEQ ID NO:22), KKGWP (SEQ ID NO:23), KLGWP (SEQ ID NO:24), LKGWP (SEQ ID NO:25), LLGWP (SEQ ID NO:26), RSYNL (SEQ ID NO:27), RSYNK (SEQ ID NO:28), kYGEV (SEQ ID NO:51), VHkSG (SEQ ID NO:52), QkHGP (SEQ ID NO:53), TkHGP (SEQ ID NO:54), YDLQr (SEQ ID NO:55), YDLTr (SEQ ID NO:56), YDkQr (SEQ ID NO:57), YDkTr (SEQ ID NO:58), kkGWP (SEQ ID NO:59), kLGWP (SEQ ID NO:60), LkGWP (SEQ ID NO:61), rSYNL (SEQ ID NO:62), rSYNk (SEQ ID NO:63), kygev (SEQ ID NO:64), vhksg (SEQ ID NO:65), qkhgp (SEQ ID NO:66), tkhgp (SEQ ID NO:67), ydlqr (SEQ ID NO:68), ydltr (SEQ ID NO:69), ydkqr (SEQ ID NO:70), ydktr (SEQ ID NO:71), kkgwp (SEQ ID NO:72), klgwp (SEQ ID NO:73), lkgwp (SEQ ID NO:74), rsynl (SEQ ID NO:75), rsynk (SEQ ID NO:76), rhfrl (SEQ ID NO:44), nrfff (SEQ ID NO:45), and rkhyh (SEQ ID NO:46),
wherein the first ligand is cyclic, and wherein the second ligand is cyclic.